Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Non-Current Debt: 2022-2025

Historic Non-Current Debt for Immunocore Holdings (IMCR) over the last 2 years, with Sep 2025 value amounting to $392.6 million.

  • Immunocore Holdings' Non-Current Debt rose 0.54% to $392.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.6 million, marking a year-over-year increase of 0.54%. This contributed to the annual value of $391.0 million for FY2024, which is 714.42% up from last year.
  • Per Immunocore Holdings' latest filing, its Non-Current Debt stood at $392.6 million for Q3 2025, which was up 0.13% from $392.1 million recorded in Q2 2025.
  • Over the past 5 years, Immunocore Holdings' Non-Current Debt peaked at $438.1 million during Q2 2024, and registered a low of $47.8 million during Q4 2022.
  • For the 3-year period, Immunocore Holdings' Non-Current Debt averaged around $360.2 million, with its median value being $391.8 million (2025).
  • Its Non-Current Debt has fluctuated over the past 5 years, first surged by 714.42% in 2024, then decreased by 10.52% in 2025.
  • Immunocore Holdings' Non-Current Debt (Quarterly) stood at $47.8 million in 2022, then increased by 0.43% to $48.0 million in 2023, then spiked by 714.42% to $391.0 million in 2024, then climbed by 0.54% to $392.6 million in 2025.
  • Its Non-Current Debt stands at $392.6 million for Q3 2025, versus $392.1 million for Q2 2025 and $391.5 million for Q1 2025.